nach oben

Erschienen in:

26.02.2019 | Neuro

Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients

verfasst von: Daniel Paech, Constantin Dreher, Sebastian Regnery, Jan-Eric Meissner, Steffen Goerke, Johannes Windschuh, Johanna Oberhollenzer, Miriam Schultheiss, Katerina Deike-Hofmann, Sebastian Bickelhaupt, Alexander Radbruch, Moritz Zaiss, Andreas Unterberg, Wolfgang Wick, Martin Bendszus, Peter Bachert, Mark E. Ladd, Heinz-Peter Schlemmer

Erschienen in: European Radiology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The purpose of this study was to investigate the association of relaxation-compensated chemical exchange saturation transfer (CEST) MRI with overall survival (OS) and progression-free survival (PFS) in newly diagnosed high-grade glioma (HGG) patients.

Methods

Twenty-six patients with newly diagnosed high-grade glioma (WHO grades III–IV) were included in this prospective IRB-approved study. CEST MRI was performed on a 7.0-T whole-body scanner. Association of patient OS/PFS with relaxation-compensated CEST MRI (amide proton transfer (APT), relayed nuclear Overhauser effect (rNOE)/NOE, downfield-rNOE-suppressed APT (dns-APT)) and diffusion-weighted imaging (apparent diffusion coefficient) were assessed using the univariate Cox proportional hazards regression model. Hazard ratios (HRs) and corresponding 95% confidence intervals were calculated. Furthermore, OS/PFS association with clinical parameters (age, gender, O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status, and therapy: biopsy + radio-chemotherapy vs. debulking surgery + radio-chemotherapy) were tested accordingly.

Results

Relaxation-compensated APT MRI was significantly correlated with patient OS (HR = 3.15, p = 0.02) and PFS (HR = 1.83, p = 0.009). The strongest association with PFS was found for the dns-APT metric (HR = 2.61, p = 0.002). These results still stand for the relaxation-compensated APT contrasts in a homogenous subcohort of n = 22 glioblastoma patients with isocitrate dehydrogenase (IDH) wild-type status. Among the tested clinical parameters, patient age (HR = 1.1, p = 0.001) and therapy (HR = 3.68, p = 0.026) were significant for OS; age additionally for PFS (HR = 1.04, p = 0.048).

Conclusion

Relaxation-compensated APT MRI signal intensity is associated with overall survival and progression-free survival in newly diagnosed, previously untreated glioma patients and may, therefore, help to customize treatment and response monitoring in the future.

Key Points

• Amide proton transfer (APT) MRI signal intensity is associated with overall survival and progression in glioma patients.

• Relaxation compensation enhances the information value of APT MRI in tumors.

• Chemical exchange saturation transfer (CEST) MRI may serve as a non-invasive biomarker to predict prognosis and customize treatment.

Nur mit Berechtigung zugänglich

Kim KB (2014) PFS as a surrogate for overall survival in metastatic melanoma. Lancet Oncol 15:246–248CrossRefPubMed

Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG (2010) Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol 12:520–527

Stupp R, Roila F (2009) Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):126–128PubMed

Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedPubMedCentral

Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003CrossRefPubMed

Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507CrossRefPubMed

Cerqua R, Balestrini S, Perozzi C et al (2016) Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme. Neurol Sci 37:23–29CrossRefPubMed

Henson JW, Gaviani P, Gonzalez RG (2005) MRI in treatment of adult gliomas. Lancet Oncol 6:167–175CrossRefPubMed

Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ (2017) Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 134(3):495–504

10.

Pope WB, Qiao XJ, Kim HJ et al (2012) Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 108:491–498CrossRefPubMedPubMedCentral

11.

Oh J, Henry RG, Pirzkall A et al (2004) Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-n-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 19:546–554CrossRefPubMed

12.

Ellingson BM, Cloughesy TF, Lai A et al (2011) Graded functional diffusion map–defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:1151–1161

13.

Higano S, Yun X, Kumabe T et al (2006) Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 241:839–846CrossRefPubMed

14.

Law M, Young RJ, Babb JS et al (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490–498CrossRefPubMed

15.

Hamstra DA, Chenevert TL, Moffat BA et al (2005) Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 102:16759–16764CrossRefPubMedPubMedCentral

16.

Bonekamp D, Deike K, Wiestler B et al (2015) Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques. J Magn Reson Imaging 42:87–96CrossRefPubMed

17.

Burth S, Kickingereder P, Eidel O et al (2016) Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Neuro Oncol 18:1673–1679

18.

Wiestler B, Kluge A, Lukas M et al (2016) Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma. Sci Rep 6:35142CrossRefPubMedPubMedCentral

19.

Kickingereder P, Götz M, Muschelli J et al (2016) Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response. Clin Cancer Res 22:5765–5771

20.

Lao J, Chen Y, Li ZC et al (2017) A deep learning-based radiomics model for prediction of survival in glioblastoma multiforme. Sci Rep 7:10353CrossRefPubMedPubMedCentral

21.

Jones CK, Huang A, Xu J et al (2013) Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T. Neuroimage 77:114–124CrossRefPubMed

22.

Jin T, Wang P, Zong X, Kim SG (2013) MR imaging of the amide-proton transfer effect and the pH-insensitive nuclear overhauser effect at 9.4 T. Magn Reson Med 69:760–770CrossRefPubMed

23.

Zaiss M, Kunz P, Goerke S, Radbruch A, Bachert P (2013) MR imaging of protein folding in vitro employing nuclear-Overhauser-mediated saturation transfer. NMR Biomed 26:1815–1822CrossRefPubMed

24.

Goerke S, Zaiss M, Kunz P et al (2015) Signature of protein unfolding in chemical exchange saturation transfer imaging. NMR Biomed 28:906–913CrossRefPubMed

25.

Longo DL, Di Gregorio E, Abategiovanni R et al (2014) Chemical exchange saturation transfer (CEST): an efficient tool for detecting molecular information on proteins’ behaviour. Analyst 139:2687–2690CrossRefPubMed

26.

Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC (2003) Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med 9:1085–1090CrossRefPubMed

27.

Sun PZ, Benner T, Copen WA, Sorensen AG (2010) Early experience of translating pH-weighted MRI to image human subjects at 3 Tesla. Stroke 41:S147–S151CrossRefPubMedPubMedCentral

28.

Zaiss M, Xu J, Goerke S et al (2014) Inverse Z-spectrum analysis for spillover-, MT-, and T1-corrected steady-state pulsed CEST-MRI--application to pH-weighted MRI of acute stroke. NMR Biomed 27:240–252CrossRefPubMedPubMedCentral

29.

Zhou J, Lal B, Wilson DA, Laterra J, van Zijl PC (2003) Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med 50:1120–1126

30.

Zhou J, Blakeley JO, Hua J et al (2008) Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med 60:842–849CrossRefPubMedPubMedCentral

31.

Togao O, Yoshiura T, Keupp J et al (2014) Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro Oncol 16:441–448

32.

Paech D, Windschuh J, Oberhollenzer J et al (2018) Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multi-pool CEST MRI at 7.0 Tesla. Neuro Oncol 20(12):1661–1671CrossRefPubMedPubMedCentral

33.

Zaiss M, Windschuh J, Paech D et al (2015) Relaxation-compensated CEST-MRI of the human brain at 7 T: unbiased insight into NOE and amide signal changes in human glioblastoma. Neuroimage 112:180–188

34.

Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820CrossRefPubMed

35.

Regnery S, Adeberg S, Dreher C et al (2018) Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. Oncotarget 9:28772–28783CrossRefPubMedPubMedCentral

36.

Zaiss M, Windschuh J, Goerke S et al (2017) Downfield-NOE-suppressed amide-CEST-MRI at 7 Tesla provides a unique contrast in human glioblastoma. Magn Reson Med 77:196–208CrossRefPubMed

37.

Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMed

38.

Zaiss M, Zu Z, Xu J et al (2015) A combined analytical solution for chemical exchange saturation transfer and semi-solid magnetization transfer. NMR Biomed 28:217–230CrossRefPubMed

39.

Schuenke P, Windschuh J, Roeloffs V, Ladd ME, Bachert P, Zaiss M (2017) Simultaneous mapping of water shift and B1 (WASABI)—application to field-inhomogeneity correction of CESTMRI data. Magn Reson Med 77:571–580CrossRefPubMed

40.

Windschuh J, Zaiss M, Meissner JE et al (2015) Correction of B1-inhomogeneities for relaxation-compensated CEST imaging at 7 T. NMR Biomed 28:529–537CrossRefPubMed

41.

Nolden M, Zelzer S, Seitel A et al (2013) The Medical Imaging Interaction Toolkit: challenges and advances: 10 years of open-source development. Int J Comput Assist Radiol Surg 8:607–620CrossRefPubMed

42.

Shanshan J, Tianyu Z, Eberhart GC et al (2017) Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI. Magn Reson Med 78:1100–1109CrossRef

43.

Paech D, Zaiss M, Meissner JE et al (2014) Nuclear Overhauser enhancement mediated chemical exchange saturation transfer imaging at 7 tesla in glioblastoma patients. PLoS One 9:e104181

44.

Desmond KL, Mehrabian H, Chavez S et al (2017) Chemical exchange saturation transfer for predicting response to stereotactic radiosurgery in human brain metastasis. Magn Reson Med 78:1110–1120CrossRefPubMed

45.

Paech D, Burth S, Windschuh J et al (2015) Nuclear Overhauser enhancement imaging of glioblastoma at 7 Tesla: region specific correlation with apparent diffusion coefficient and histology. PLoS One 10:e0121220CrossRefPubMedPubMedCentral

46.

Choi YS, Ahn SS, Lee SK et al (2017) Amide proton transfer imaging to discriminate between low- and high-grade gliomas: added value to apparent diffusion coefficient and relative cerebral blood volume. Eur Radiol 27:3181–3189

47.

Sakata A, Okada T, Yamamoto A et al (2015) Grading glial tumors with amide proton transfer MR imaging: different analytical approaches. J Neurooncol 122:339–348CrossRefPubMed

48.

Jiang S, Rui Q, Wang Y et al (2017) Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics. Eur Radiol 28(5):2115–2123CrossRefPubMedPubMedCentral

49.

Heo H-Y, Zhang Y, Jiang S, Lee DH, Zhou J (2016) Quantitative assessment of amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging with extrapolated semisolid magnetization transfer reference (EMR) signals: II. Comparison of three EMR models and application to human brain glioma at 3 Tesla. Magn Reson Med 75:1630–1639

50.

Xu J, Yadav NN, Bar-Shir A et al (2014) Variable delay multi-pulse train for fast chemical exchange saturation transfer and relayed-nuclear overhauser enhancement MRI. Magn Reson Med 71:1798–1812CrossRefPubMed

Titel: Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients
verfasst von: Daniel Paech
Constantin Dreher
Sebastian Regnery
Jan-Eric Meissner
Steffen Goerke
Johannes Windschuh
Johanna Oberhollenzer
Miriam Schultheiss
Katerina Deike-Hofmann
Sebastian Bickelhaupt
Alexander Radbruch
Moritz Zaiss
Andreas Unterberg
Wolfgang Wick
Martin Bendszus
Peter Bachert
Mark E. Ladd
Heinz-Peter Schlemmer
Publikationsdatum: 26.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 9/2019
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-019-06066-2

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients